DMAC
DiaMedica Therapeutics (DMAC)
$67
About DiaMedica Therapeutics (DMAC)
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
Details
Daily high
$5.70
Daily low
$5.32
Price at open
$5.40
52 Week High
$6.41
52 Week Low
$2.14
Market cap
242.5M
Dividend yield
0.00%
Volume
63,804
Avg. volume
94,470
P/E ratio
-10.26
DiaMedica Therapeutics News
Details
Daily high
$5.70
Daily low
$5.32
Price at open
$5.40
52 Week High
$6.41
52 Week Low
$2.14
Market cap
242.5M
Dividend yield
0.00%
Volume
63,804
Avg. volume
94,470
P/E ratio
-10.26